Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience

被引：0
|
作者：
Mukku, R. B. [1 ]
Verma, S. [1 ]
Liu, J. [1 ]
Steingart, R. [1 ]
Hudis, C. [1 ]
Yu, A. F. [1 ]
Dang, C. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-09
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era
    Nozawa, Kazuki
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Funahashi, Yoriko
    Kogure, Yoshihito
    Kawasaki, Tomonori
    Kato, Aya
    Kitagawa, Chiyoe
    Hayashi, Takako
    Morita, Takako
    Ichihara, Shu
    Saka, Hideo
    Sato, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [23] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [24] Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
    Palmieri, Carlo
    Shah, Deep
    Krell, Jonathan
    Gojis, Ondrej
    Hogben, Katy
    Riddle, Pippa
    Ahmad, Riz
    Tat, Tri
    Fox, Kevin
    Porter, Andrew
    Mahmoud, Sarah
    Kirschke, Stephanie
    Shousha, Sami
    Gudi, Mihir
    Coombes, R. Charles
    Leonard, Robert
    Cleator, Susan
    CLINICAL BREAST CANCER, 2011, 11 (02) : 93 - 102
  • [25] Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
    Down, Sue K.
    Lucas, Olivia
    Benson, John R.
    Wishart, Gordon C.
    ONCOLOGY LETTERS, 2014, 8 (06) : 2757 - 2761
  • [26] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [27] Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients
    Sawaki, Masataka
    Taira, Naruto
    Uemura, Yukari
    Saito, Tsuyoshi
    Baba, Shinichi
    Kobayashi, Kokoro
    Kawashima, Hiroaki
    Tsuneizumi, Michiko
    Sagawa, Noriko
    Bando, Hiroko
    Takahashi, Masato
    Yamaguchi, Miki
    Takashima, Tsutomu
    Nakayama, Takahiro
    Kashiwaba, Masahiro
    Mizuno, Toshiro
    Yamamoto, Yutaka
    Iwata, Hiroji
    Kawahara, Takuya
    Ohashi, Yasuo
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3743 - +
  • [28] Optimal duration of trastuzumab for early HER2-positive breast cancer
    Specht, Jennifer M.
    Davidson, Nancy E.
    LANCET, 2017, 389 (10075): : 1167 - 1168
  • [29] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [30] Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
    Canale, Maria laura
    Casolo, Giancarlo
    Donati, Sara
    Bisceglia, Irma
    Puccetti, Cheti
    Amoroso, Domenico
    Venturini, Elio
    Maurea, Nicola
    Turazza, Fabio maria
    Camerini, Andrea
    IN VIVO, 2023, 37 (05): : 2139 - 2146
12345